Bora Pharmaceuticals Inks $250M Manufacturing Deal With GSK

Key Takeaways

Bora Pharmaceuticals and GSK have signed a five-year global manufacturing contract valued at $250 million. The deal provides a significant, stable revenue stream for Bora and secures a key part of the supply chain for GSK.

1. Bora Pharmaceuticals has entered into a five-year, $250 million global manufacturing agreement with pharmaceutical giant GSK.
2. The contract provides Bora with a stable, long-term revenue stream, significantly enhancing its financial outlook and market position.
3. For GSK, the deal represents a strategic move to fortify its global supply chain, ensuring production continuity for its products.